resmain: resmonistat for ctcl maintenance
Published 3 years ago • 35 plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
1:23
resmain: hdac inhibitor resminostat for ctcl
-
1:32
resminostat maintenance for advanced cutaneous lymphoma: resmain study
-
1:48
do all patients require maintenance therapy following allosct?
-
3:15
updates on the use of btkis in the treatment of mcl
-
1:18
involving the patient in treatment decisions for cll
-
2:38
ibrutinib treatment for cll does not increase the incidence of richter’s transformation
-
2:04
autologous transplantation followed by maintenance vs maintenance alone in patients with mcl
-
1:19
telomerase inhibition as a novel targeted therapy for myelofibrosis
-
6:54
biomarker-guided treatment of cll in the chemo-free era
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
1:47
shared treatment decision-making
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
2:09
heart transplantation in attr amyloidosis
-
1:36
improve study update: safety and efficacy of venetoclax retreatment in r/r cll
-
1:02
maintenance therapy following treatment for amyloidosis
-
6:28
outcomes following first-line therapy in routine clinical practice in alcl
-
1:53
the future of multiple myeloma treatment
-
1:14
the potential of celmods for the treatment of r/r multiple myeloma
-
3:40
master class in transplantation and hematology: highlights
-
1:52
evaluating surrogacy endpoints in cll clinical trials
-
2:13
resistance mechanisms in cll and the importance of genomic re-testing